Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review
Authors:
- Ran Hai-HongRHRan Hai-Hong
- Zhang RanZRZhang Ran
- Lu Xue-ChunLXLu Xue-Chun
- Yang BoYBYang Bo
- Fan HuiFHFan Hui
- Zhu Hong-LiZHZhu Hong-Li
Open Access
- 20 December 2012
- journal article
- Published by Tsinghua University Press in Journal of Geriatric Cardiology
- Vol. 9 (4) , 411-414
Abstract
Because it is safe and well tolerated, imatinib is a standard first-line therapy for chronic myeloid leukemia (CML). Although there have been sporadic reports of imatinib-induced cardiotoxicity, including left ventricle (LV) dysfunction and heart failure, the evidence for it is contradictory. Here, we reported a case of an 88-year-old male patient with CML developed decompensated heart failure following imatinib therapy. Four days after the initiation of imatinib, the patient developed orthopnea, edema and a pleural effusion accompanied by abdominal distension, nausea and vomiting. The chest X-ray film showed an enlarged cardiac profile. The echocardiogram demonstrated a decreased LV ejection fraction and enlarged left-side cardiac chambers. B-type natriuretic peptide concentrations were markedly increased. The patient recovered soon after the withdrawal of imatinib and introduction of comprehensive therapy for heart failure. Imatinib-induced cardiotoxicity in elderly patients is a potentially serious complication that merits further evaluation.Keywords
This publication has 21 references indexed in Scilit:
- Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET systemLeukemia Research, 2011
- A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinibLeukemia Research, 2011
- Congestive heart failure during imatinib mesylate treatmentInternational Journal of Cardiology, 2010
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- An evaluation of the cardiotoxicity of imatinib mesylateLeukemia Research, 2008
- Targeted chronic myeloid leukemia therapy: Seeking a cureAmerican Journal of Health-System Pharmacy, 2007
- BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2007
- Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005European Journal of Cancer, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Cardiotoxicity of the cancer therapeutic agent imatinib mesylateNature Medicine, 2006